Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This micro-cap stock is leading the US graphite revolution (click to learn more) Eric Sprott Announces Changes to His Holdings in Honey Badger Silver Inc. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Grace Therapeutics Inc GRCE

Healthcare Biotechnology
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a... see more

Recent & Breaking News (NDAQ:GRCE)

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

GlobeNewswire February 12, 2024

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

GlobeNewswire February 1, 2024

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

GlobeNewswire December 13, 2023

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire November 13, 2023

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

GlobeNewswire October 23, 2023

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

GlobeNewswire October 4, 2023

Acasti Announces $7.5 Million Private Placement Equity Financing

GlobeNewswire September 26, 2023

Acasti to Participate in the H.C. Wainwright Global Investment Conference

GlobeNewswire September 6, 2023

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire August 11, 2023

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

GlobeNewswire August 9, 2023

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

PR Newswire July 10, 2023

Acasti Pharma Announces 1-for-6 Reverse Stock Split

PR Newswire July 7, 2023

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

PR Newswire July 5, 2023

Acasti Pharma Reports Fiscal Year 2023 Operational Results

PR Newswire June 23, 2023

Acasti Announces Appointment of New Scientific Advisory Board Members

PR Newswire June 22, 2023

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

PR Newswire May 17, 2023

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

PR Newswire May 8, 2023

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

PR Newswire April 4, 2023

Acasti Announces Appointment of Prashant Kohli as CEO

PR Newswire April 4, 2023

Acasti Pharma Inc. Announces the Resignation of a Director

PR Newswire March 30, 2023

Podcasts